Exscientia PLC ADR EXAI
News
Exscientia Business Update for Second Quarter and First Half 2024
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA
Exscientia Shares Rally Premarket on Lucrative Merck Deal
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery